Astellas writes off $560M loss, dropping gene therapy programs, oncology antibody
After repeated setbacks in gene therapy, Astellas is writing off more than half a billion dollars in losses — and gutting candidates that were once thought …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
